Viridian Therapeutics
Optimized monoclonal antibodies for rare autoimmune diseases
- Sector
- Biotech
- Headquarters
- WALTHAM, MA
- Founded
- 2020
- Latest Form D
- $27M, Sep 2020
- Total capital
- $29M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $29M
- 2 Form D · last Sep 2020
- 73 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 35 pending · first 2023
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$27M
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Jonathan ViolinExecutive Officer, DirectorNamed in SEC Form D filings
- Peter HarwinDirectorNamed in SEC Form D filings
- Tomas KiselakDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 40- PendingCompositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseUSPTOApplication 19287281
- PendingMethods Of Treating Chronic Thyroid Eye DiseaseUSPTOApplication 19442626
- GrantedCompositions And Methods For Treatment Of Thyroid Eye DiseaseUSPTOUS 12,600,788
Show all 40 patent records
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseAug 27, 2026 · Application 19287281Pending
- Methods Of Treating Chronic Thyroid Eye DiseaseMay 14, 2026 · Application 19442626Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApr 14, 2026 · US 12,600,788Granted
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApr 7, 2026 · US 12,595,309Granted
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 9, 2025 · Application 19242715Pending
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseSep 2, 2025 · US 12,404,337Granted
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseSep 2, 2025 · US 12,404,335Granted
- Fcrn Antagonists With Improved Half-life And Methods Of UseMay 15, 2025 · Application 18917838Pending
- Pharmaceutical Compositions Of ANTI-IGF-1R AntibodiesMar 27, 2025 · Application 18827383Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 31, 2024 · Application 18760539Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 24, 2024 · Application 18749821Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 17, 2024 · Application 18760575Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseFeb 8, 2024 · Application 18364620Pending
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseMar 16, 2023 · Application 17818798Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseJan 10, 2023 · US 11,548,951Granted
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseSep 1, 2022 · Application 17724639Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseAug 25, 2022 · Application 17501430Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseAug 25, 2022 · Application 17501362Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseJul 28, 2022 · Application 17450872Pending
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63656371Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63619034Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63619028Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63619033Pending
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63611151Pending
- Methods Of Treating Active And Chronic Thyroid Eye DiseaseApplication 63512468Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2023060207Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2023060206Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2022082214Pending
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2022074764Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63266549Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63266548Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63293242Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2021054914Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2021054907Pending
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63261744Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63261742Pending
- Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63260133Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63260130Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63201978Pending
- Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63091839Pending
Related companies, and why
- REVOPSIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Elevian, Inc.Similar federal contract value in Biotech · null in contracts
- Momentum Superior Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- Agenebio, Inc.Similar federal contract value in Biotech · null in contracts
- FILAMENTECH. INC.Similar federal contract value in Biotech · null in contracts
- Magnet BiomedicineSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .